Anika Therapeutics, Inc.
ANIK
$14.88
-$0.14-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 58.76% | 58.89% | 51.13% | 58.60% | 65.08% |
| Total Depreciation and Amortization | 6.12% | 0.45% | 660.63% | 69.95% | 26.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.29% | -51.76% | -56.31% | -62.88% | -64.14% |
| Change in Net Operating Assets | 8.74% | 94.36% | 86.14% | 43.25% | 37.00% |
| Cash from Operations | 19.87% | 107.07% | 9.04% | -29.67% | 216.84% |
| Capital Expenditure | 27.89% | -4.73% | -6.16% | 28.16% | -28.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00% | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 31.77% | 95.19% | 78.50% | 74.46% | 16.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -34.30% | -36.22% | -32.12% | -32.12% | -9.83% |
| Repurchase of Common Stock | -26.03% | -16.06% | -189.44% | -181.10% | -61.78% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.73% | 17.11% | -51.09% | -363.32% | -127.58% |
| Foreign Exchange rate Adjustments | 79.27% | 122.34% | 111.73% | 238.63% | -1,466.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.05% | 102.05% | 47.14% | -329.30% | -37.36% |